1. Stocks
    2. /
  2. Pfizer Inc. (NYSE: PFE)
    3. /

Pfizer Inc. (NYSE: PFE) Share Price and News

$24.80 $-1.22 (-4.7%) Saturday, 16 November 2024 at 8:00:00 am Australian Eastern Daylight Time

Pfizer Inc. Chart and Price Data

About Pfizer

Last updated 16-11-2024, 08:00:00am AEDT
Current Price $24.80
Change $-1.22 (-4.7%)
Close Price $24.80
Open Price $25.70
Bid $24.92
Ask $24.95
Day Range $24.48 - $25.70
Year Range $24.48 - $31.54
Volume 131,074,383
Average Volume 35,165,136
Market Cap $140,541,352,000.00
Earnings Per Share $0.74

    • Pfizer Inc. (NYSE: PFE)
    Latest News

    coronavirus vaccine represented by gloved hand drawing down from syringe
    International Stock News

    Johnson & Johnson coronavirus vaccine wins FDA authorisation

    | Eric Volkman

    The big pharmaceutical company's jab has some important advantages.

    Read more »

    covid vaccine shares represented by numbers 2021 with the one displayed as syringe
    Coronavirus News

    Pfizer COVID-19 vaccine given green light for use in Australia

    | Mitchell Lawler

    The TGA has approved the Pfizer COVID-19 vaccine for use in Australia. We take a look at some of the…

    Read more »

    Share Market News

    CV Check (ASX:CV1) share price flat on results update

    | Aaron Teboneras

    The CV Check Ltd (ASX: CV1) share price remains unchanged today following the release of its Q2 FY21 scorecard.

    Read more »

    Hand with blue medical gloves holds vials of coronavirus vaccines
    International Stock News

    Moderna's stock has surged 488% in 2020: Is it a buy for 2021?

    | Sushree Mohanty

    This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?

    Read more »

    asx share price boosted by us investment represented by hand waving US flag across winning athlete
    Share Market News

    Here are the US shares ASX investors are buying

    | Sebastian Bowen

    AirBnB Inc (NASDAQ: ABNB) and Tesla Inc (NASDAQ: TSLA) were amongst the US shares that ASX investors were buying last…

    Read more »

    Vaccine vials sitting on top of a pile of US cash
    International Stock News

    The most popular coronavirus stock may lose half its value by 2023

    | Sean Williams

    This as-of-now unstoppable COVID-19 stock might be one of the worst investments going forward.

    Read more »

    vials of medication labelled with COVID-19 vaccine stickers
    Share Market News

    CSL (ASX:CSL) share price on watch after hints of 'far more robust' vaccine

    | Bernd Struben

    Australian global biotech giant CSL Limited didn't win the sprint for a coronavirus vaccine. But it may lead the marathon.

    Read more »

    woman waering face mask holding vial of covid-19 vaccine
    International Stock News

    Why Pfizer and BioNTech stocks popped Wednesday

    | Joe Tenebruso

    The healthcare leaders became the first to receive emergency authorization for their coronavirus vaccine.

    Read more »

    travel asx share price represented by suitcase wearing covid mask
    Share Gainers

    Which ASX travel shares performed the best in November? 

    | Lina Lim

    On the back of vaccine hopes and reopening borders, which ASX travel shares performed the best in November? We take…

    Read more »

    doctor holding covid-19 vaccine bottle
    International Stock News

    3 key advantages Moderna holds over Pfizer and AstraZeneca

    | Keith Speights

    They could add up to make Moderna a much bigger winner for investors than either of the two big pharma…

    Read more »

    Doctor holding small world globe in one hand and a Covid vaccine needle in the other
    International Stock News

    Why AstraZeneca's potential vaccine is more exciting than you think

    | Jason Hawthorne

    Investors are missing the big picture in the drugmaker's vaccine announcement.

    Read more »

    Cash piled up in the middle of a bear trap symbolising risky investments
    International Stock News

    Why Moderna Is Less Risky Than You Think

    | Manali Bhade

    Its coronavirus vaccine will likely be successful; its technology has huge potential; and the company has a healthy balance sheet.

    Read more »

    Profile

    since

    Note